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Abstract
Background: Most clinical trial publications include figures, but there is little guidance on what
results should be displayed as figures and how.
Purpose: To evaluate the current use of figures in Trial reports, and to make constructive
suggestions for future practice.
Methods: We surveyed all 77 reports of randomised controlled trials in five general medical
journals during November 2006 to January 2007. The numbers and types of figures were
determined, and then each Figure was assessed for its style, content, clarity and suitability. As a
consequence, guidelines are developed for presenting figures, both in general and for each specific
common type of Figure.
Results: Most trial reports contained one to three figures, mean 2.3 per article. The four main
types were flow diagram, Kaplan Meier plot, Forest plot (for subgroup analyses) and repeated
measures over time: these accounted for 92% of all figures published. For each type of figure there
is a considerable diversity of practice in both style and content which we illustrate with selected
examples of both good and bad practice. Some pointers on what to do, and what to avoid, are
derived from our critical evaluation of these articles' use of figures.
Conclusion: There is considerable scope for authors to improve their use of figures in clinical trial
reports, as regards which figures to choose, their style of presentation and labelling, and their
specific content. Particular improvements are needed for the four main types of figures commonly
used.
Introduction
Much has been written about how to visually display
quantitative information, [1-4] and some attention has
been paid to the specific constraints of including figures in
Medical journal articles [5-9]. In this article we focus on
the use of figures in reports of randomised clinical trials,
for which there is little specific guidance available at
present[10].
In order to understand current practice, we undertook a
survey of recent publications of randomized clinical trial
in major general medical journals. This provides objective
evidence as to the extent of use of figures in trial reports,
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including which types of figure are chosen by authors.
This survey then facilitates constructive critical appraisal
of both the good features and the limitations of how
authors and journals are utilizing figures for visual display
of results.
In formulating our recommendations for improved use of
figures in future trial reports, we give particular attention
to each main type of figure used and draw on published
examples to illustrate the specific features of interest.
Methods
We identified all 77 reports of randomised clinical trials
published in November 2006 to January 2007 in the fol-
lowing five major general medical journals: Archives of
Internal Medicine, British Medical Journal (BMJ), Journal
of American Medical Association (JAMA), Lancet and New
England Journal of Medicine (NEJM). BMJ publishes a
shorter version of each article in print, and a larger version
on-line. We have studied the longer versions.
For each article we first noted the number and types of fig-
ure included, restricting attention to figures displaying data.
There were nine other Figures, mostly schema of trial pro-
tocols. From past guidance in the literature and our own
previous surveys of trial reports in 1999 [11,12] and 2005
[13] we formulated a prior list of issues that we thought
were pertinent to the style and content of both figures in
general and the specific common types of figures used in
trial reports. With this list in mind, we carefully inspected
every figure included in our survey regarding the appropri-
ateness of its presentation and content. This exercise led us
to refine our list (presented as recommendation at end of
the Discussion) as to what constitutes good and bad prac-
tice in the use of figures, and to select specific examples to
add practicality to our illustrative points.
Results
Table 1 displays the main facts from our survey. In this
three month period, the New England Journal published
more trial reports than each of the other four journals.
Most articles contained one, two or three figures and there
were 175 figures in 77 articles, mean 2.3 figures per article.
The most common types of figure were:
Flow diagram (66 articles) describing the flow of partici-
pants through the various stages of the trial.
Kaplan Meier plot (32 articles) comparing treatments for
time-to-event (survival) outcomes.
Forest plot (21 articles) displaying several estimates of
treatment effect, usually by subgroups of patients, but
occasionally by other comparative features.
Repeated measures plot (20 articles) displaying mean
outcomes at baseline and several follow-up times by treat-
ment group.
These four types of plot accounted for 92% of figures in
our survey. The remainder comprised bar chart (7 arti-
cles), individual patient data display (3 articles), box
plot (2 articles), cumulative distributions (1 article).
We now turn attention to the style and content of specific
types of figure. From the survey, we have chosen four
examples of each main type of Figure, plus a few other
examples (20 examples in all) to illustrate the main fea-
tures to consider, include, and sometimes avoid, in one's
use of figures.
The flow diagram is an integral part of the CONSORT
guidelines [14,15], adopted by most major journals.
Hence it is meant to be a mandatory requirement for pub-
lication in all journals we surveyed, except NEJM which
had flow diagrams for half its clinical trial articles. Its aim
is to display the flow of participants through each stage,
specifically for each randomized group reporting the
numbers randomly assigned, receiving intended treat-
ment, completing study protocol, and analysed for the
primary outcome.
Table 1: Figures in Reports of Clinical Trials in Five Medical 
Journals during November 2006 to January 2007.
Journal
No. of articles 
(total 77)
Annals of Internal Medicine 7
British Medical Journal 16
Journal of American Medical Association 14
Lancet 12
New England Journal of Medicine 28
No. of Figures in each article
None 1
One 23
Two 22
Three 19
Four 11
Seven 1
Types of Figure in each article*
Flow Diagram 66
Kaplan Meier plot 32
Forest plot 21
Repeated measures 20
Bar chart 7
Individual patient data 3
Box plot 2
Cumulative distribution 1
*Some articles had one type of Figure several times. In this Table each 
type of Figure is only counted once per article.
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Figure 1 is a straightforward example. One limitation is
that it does not reveal who the participants are and what
type of intervention was received. This could have been
achieved by line one starting "522 randomized partici-
pants with impaired glucose tolerance", and line two
inserting "life-style" before "intervention". Information
on loss-to-follow up is important. This figure helpfully
gives the numbers experiencing the primary outcome, so
that the readers see upfront that few diabetic cases
occurred in the intervention group.
Figure 2 includes some useful extra features: the numbers
of patients screened for potential inclusion, the reasons
for exclusions from randomization, and the numbers who
did not receive their intended treatment.
In trials with a more complex design, the flow diagram is
especially useful. For instance, Figure 3 illustrates a partial
two way factorial design, in which the second randomiza-
tion concerned the timing of one treatment. To clarify the
full extent of randomization, row two could have inserted
"randomly" before "assigned" each time.
Figure 4 illustrates one stylistic problem in flow diagrams,
which is that words can get repeated many times in rou-
tine display with more than two treatments. Thus if this
figure had been displayed as a table instead, with appro-
priate row and column headings, the numbers of words
would have been reduced by more than half, with no loss
of information.
The Kaplan Meier plot is the routine method of displaying
time-to-event (survival) data by treatment group [12]. The
event may be death, a non-fatal event (e.g. disease recur-
rence), a composite outcome (e.g. time to death, myocar-
dial infarction or stroke whichever occurs first) or
occasionally a good outcome (e.g. time to recovery).
Figure 5 illustrates many of the essential features. The two
treatment groups are clearly identifiable, and the axes
clearly labelled. This concerns the study's primary end-
point, which is defined in the figure's footnote. The graph
is plotted going up, i.e. cumulative % incidence, with an
appropriate maximum (25%) on the vertical scale which
allows the detail to be seen. Underneath the horizontal
axis the numbers at risk (i.e. still in follow-up and without
the primary endpoint as yet) are shown at convenient
Trial profileFigure 1
Trial profile. *After the decision to end the intervention 
period, the intervention was continued until each partici-
pant's next scheduled yearly clinic visit. End date thus varied 
from March, 2000, to Dec, 2001. † Participants who were 
lost to follow-up were treated as censored observations in 
the analyses. (Lindstrom et al.  Lancet Nov 11, 2006 p1674)
Enrollment and OutcomesFigure 2
Enrollment and Outcomes.
(REST Investigators. NEJM Jan 25, 2007 p362)
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(one year) intervals. In this case, the numbers in follow-
up get rapidly smaller in the later years. Though not
stated, it looks appears that median follow-up was around
three years, so it might have been better not to extend the
graph out to five years. The eye is naturally drawn to the
right hand end of the graph where the estimated percent-
ages become increasingly prone to random error.
A superficial glance at Figure 5 takes in the fact that the
PCI group has a slightly higher % endpoints at all times,
but this can be readily attributable to chance. Hence, it is
good practice to include the hazard ratio, its 95% CI and
the logrank P-value on the figure to clarify the (lack of)
evidence concerning a treatment difference. Figure 5's
footnote includes yet more details on treatment compari-
sons by year, which is perhaps more than is usually
warranted.
By contrast, Figure 6 has several problems. The vertical
axis is for proportion surviving rather than dead, and has
a cut-off at 0.70. This tends to deceptively exaggerate any
treatment differences. This is enhanced by the lack of
information on numbers at risk over time (i.e. how many
were censored before 500 days?) and the lack of any esti-
mates, CIs or P-values on the graph. This is all clarified in
the article: 11/132 versus 21/131 deaths, hazard ratio
0.46, 95% CI 0.22 to 0.95, logrank P = 0.015.
Figure 7 is an example of a Kaplan-Meier plot going down
covering the whole vertical scale from probability 1 to
probability 0. Since the event (defaulting from treatment)
has a low occurrence, much of the graph is empty space.
Perhaps such a plot going down is best kept for trials with
high failure rates e.g. the low survival rates in studies of
advanced cancer.
Enrollment, Randomization, and Follow-up of the Patients in the TrialFigure 3
Enrollment, Randomization, and Follow-up of the Patients in the Trial. GP denotes glycoprotein. (Stone et al.  NEJM 
Nov 23, 2006 p2205)
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One problem with most Kaplan Meier plots is the lack of
any display of statistical uncertainty, which may lead read-
ers to over-interpret any observed treatment difference.
Figure 8 is a relatively rare example where the plot
includes 95% CIs for the estimates over time. The end
result in this case is a bit too cluttered, so it might have
been better if these had been included at each year rather
than every three months. Also, standard error bars might
be preferable as they are half the width of 95% CIs.
Regardless of the method, displaying such uncertainty is
to be encouraged. Note the stepped pattern to the plots in
figure 8: this is appropriate because the outcome, mono-
therapy failure, was observed at each three-monthly visit
rather than in continuous time.
A Forest plot is a method of displaying the extent to which
the estimated treatment effect differs across various sub-
groups of patient [16,17]. Figure 9 is a relatively simple
example to explain. The estimate of treatment effect in this
instance is the odds ratio of death for albumin compared
to saline. The two subgroups are patients with baseline
albumin below or above 25 g/l and for each the odds ratio
and its 95% CI are plotted. Labels helpfully indicate that
to the left of the vertical line at odds ratio equal to one
favours albumin while to the right favours saline. Both CIs
include one which indicates non-significance at the 5%
level. However it is more meaningful to note that the two
CIs overlap somewhat, suggesting there is insufficient
evidence to claim an interaction between treatment and
Trial profileFigure 4
Trial profile. GP = general practitioner; TKR = total knee replacement. (Hay et al.  BMJ online Nov 11, 2006 p3)
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baseline albumin. This is made clear by the heterogeneity
test (sometimes called interaction test) P = 0.08.
Note the horizontal axis is on a log scale i.e. the distance
from 0.5 to 1 is the same as the distance from 1 to 2. This
makes sense in that a halving and a doubling of odds are
of equal magnitude. This use of log scale also makes all
CIs symmetric about the estimated effects. The plot use-
fully gives the overall estimated odds ratio for all patients,
and its CI. Figure 9 also gives in tabular form i) the
number of deaths and patients by treatment overall and
by subgroup and ii) the consequent odds ratios and CIs
that are already plotted. This duplication of information is
useful or repetitious, depending on the tastes of authors
and editors.
Most Forest plots in trial reports look at several subgroup
analyses, such as in Figure 10. This is for time to a com-
posite primary outcome and hence hazard ratios (and
their CIs) are displayed. One first concentrates on the
overall estimate and the fact that its 95% CI overlaps one
indicates no significant difference between PCI and med-
ical therapy. Next, most subgroup CIs have substantial
overlap with the overall point estimate at the top, which
indicates a consistency of findings across subgroups.
The one exception is age. The two CIs for younger and
older patients overlap only slightly, and the interaction
test has P = 0.05. This might provoke some interest as an
exploratory finding suggesting PCI may have more merit
in older patients. However, the authors, aware of the dan-
gers of false positive findings across multiple subgroup
analyses, mention in the footnote that P < 0.01 was the
tough pre-specified criterion for any claims of interaction.
Figure 10 also tabulates four-year event rates by treatment
and subgroup, which is a useful way of documenting
absolute risk and how it varies by subgroup. For instance,
Kaplan-Meier Curves for the Primary End Point, According to the Int ntion-to-Treat AnalysisFigure 5
Kaplan-Meier Curves for the Primary End Point, 
According to the Intention-to-Treat Analysis. The 
primary end point was the first centrally adjudicated 
occurrence of death from any cause, nonfatal reinfarction, or 
NYHA class IV heart failure requiring hospitalization or a 
stay in a short-stay unit. Kaplan-Meier estimates of the 
cumulative event rates in the PCI group and the medical 
therapy group, respectively, were 14.8% and 13.1% at 
3 years, 17.2% and 15.6% at 4 years, and 21.2% and 16.4% at 
5 years. The cumulative yearly adjusted hazard ratios for PCI 
versus medical therapy for years 1 through 5 were 1.13, 1.18, 
1.14, 1.13, and 1.16, respectively. The P value was calculated 
with the use of the log-rank test. (Hochman et al.  NEJM Dec 
7, 2006 p2403)
Survival in children on isoniazid (INH) or placeboFigure 6
Survival in children on isoniazid (INH) or placebo. (Zar et al.  
BMJ online Jan 20, 2007 p4)
Kaplan-Meier Curve of the Time to Defaulting From Treat-ment by Study G oupFigure 7
Kaplan-Meier Curve of the Time to Defaulting From 
Treatment by Study Group. RR indicates risk ratio; CI, 
confidence interval. (Thiam et al.  JAMA Jan 24, 2007 p384)
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event rates are higher for patients with ejection fraction <
50%. The figure's footnote is unduly long, and perhaps
much of it should have been in the Methods section
instead.
Figure 11 clarifies some other features of a Forest plot. In
all such plots the more events that occur in a subgroup the
narrower the CI. To help the eye to focus on these more
precise estimates, they are given a larger square blob,
whereas in contrast small subgroups have a tinier square.
Figure 11 also tabulates the numbers of patients with the
event, by treatment and subgroup. This helps give reality
to the plotted hazard ratios. The plot includes a vertical
line at the overall effect, which helps the eye to spot any
potentially deviant subgroups.
Figure 11 did not provide any interaction tests; instead the
text includes the comment "there was no evidence of sub-
stantial heterogeneity...." The term HR is a little blunt; to
state "hazard ratio" would be clearer. Again to give all HRs
and CIs in both figure and tabular form is unnecessarily
repetitious.
The other main use of Forest plots is for meta-analyses,
which display estimates from several related trials and
combines them into an overall combined estimate. This is
illustrated in Figure 12. To help the overall estimates and
CI stand out it is usually shown as a diamond shape.
Figure 12 is rather too minimalist as there is no additional
data provided besides the plot itself. Also the plot does
not identify which is the new trial. However, one can
deduce that while no individual trial had a significant
Kaplan-Meier Estimates of the Cumulative Incidence of Monotherapy Failure at 5 YearsFigure 8
Kaplan-Meier Estimates of the Cumulative Incidence of Monotherapy Failure at 5 Years. Treatment was consid-
ered to have failed if a patient had a confirmed or adjudicated level of fasting plasma glucose of more than 180 mg per deciliter. 
Risk reduction is listed for comparisons of pairwise groups from a baseline covariate-adjusted Cox proportional-hazards 
model. Gray's estimates of cumulative incidence adjusted for all deaths were smaller than Kaplan-Meier estimates of treatment 
failure: 10% in the rosiglitazone group, 15% in the metformin group, and 25% in the glyburide group. I bars indicate 95% CIs. 
(Kahn et al.  NEJM Dec 7, 2006 p2433)
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mortality reduction (assuming 95% CIs are plotted), the
combined estimate's CI is narrower and wholly under one
indicating overall significance. The smaller Stockholm
trial is readily spotted as a potential outlier. Other occa-
sional uses of Forest plot can be to plot treatment effects
by different periods of follow-up, different outcome
measures or different analysis methods. However, Forest
plots are mostly for subgroup analyses of binary or time-
to-event outcomes with odds ratio, relative risk or hazard
ratio estimates.
For trials with a quantitative outcome measure it is com-
mon to have repeated measures at fixed follow-up times,
and usually also at baseline. It is then usual to plot the
means by treatment over time. Figure 13 is an unduly
simple example that lacks much important information.
This only plots the means whereas it is good practice to
also have standard error bars to illustrate the statistical
uncertainty in each mean. It is also good practice to have
symbols at each mean in addition to joined lines: this
would make clear that measurements were made at 0, 3, 6
and 12 months but not at 9 months. From the figure alone
one cannot determine how strong is the evidence for
lower (better) scores in the pharmacy and physiotherapy
groups. Also, there is an inconsistency of style in that the
vertical axis of one plot starts at 0 while the other does not.
Perhaps both plots should have shown the detail with a
clearly indicated non-zero vertical origin. Lastly, there is
no indication regarding numbers of patients, though
admittedly such detail is in a separate Table.
Figure 14 presents 95% CIs for each mean, slightly offset
to enhance readability. We have a slight preference for
standard error bars instead since they are roughly half the
width. Furthermore error bars only need be shown in one
direction, going up for the top line and down for the bot-
tom line since their symmetry about each mean is known.
Figure 14 usefully incorporates a global P-value, which
clarifies that there is insufficient evidence of a treatment
difference. Again, there is no indication of the numbers of
patients involved.
In Figure 15 the authors adopt a different (often better)
approach by plotting mean changes from baseline, rather
than means, with standard error bars. Analysis of covari-
ance adjusting for baseline value is a preferred method of
inference for such data [18], and this is what these authors
mean by least-square (LS) means as explained in their
Methods section. They have used last observation carried
forward (LOCF) which is now regarded as less desirable
than an appropriate repeated measures model assuming
missing at random [19], but that is a separate issue from
assessing the figure itself. The numbers of patients by
group at each time are appropriately given below the x-
axis, though it is puzzling as to why there are fewer at 24
weeks. The footnote to Figure 15 gives the primary infer-
ence regarding treatment differences at final visit, which is
important detail that could alternatively have been in the
main text.
Figure 16 illustrates the difficulty of plotting repeated
measures with several treatment groups. Some of the
Unadjusted odds ratio (95% confidence interval) of death in all patients and in subgroups with baseline serum albumin concen-tration of 25 g/l o  less and of mor  than 25 g/lFigure 9
Unadjusted odds ratio (95% confidence interval) of death in all patients and in subgroups with baseline serum albumin concen-
tration of 25 g/l or less and of more than 25 g/l. (Heterogeneity of treatment effect in subgroups with baseline serum albumin 
concentration ≤25 g/l v >25 g/l, P = 0.08). (SAFE Study.  BMJ online Nov 18, 2006 p4)
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points are hidden behind one another and the standard
error bars are confusingly entangled. This could have been
alleviated by having the four points offset slightly at each
time. Also, with several treatments it may be better to not
join the points with lines.
Since the main inference is about baseline adjusted mean
changes this would have been conveyed better with a plot
of mean changes rather than means. From the rest of the
article, one deduces that all three intervention groups did
somewhat better than the control group at five years, a fact
Subgroup AnalysisFigu e 10
Subgroup Analysis. Hazard ratios (black squares), 95% CIs (horizontal lines), P values for the interaction between the treat-
ment effect and any subgroup variable, and cumulative estimated 4-year event rates for the primary outcome (death from any 
cause, nonfatal reinfarction, or NYHA class IV heart failure requiring hospitalization or a stay in a short-stay unit) for PCI ver-
sus medical therapy for the specified subgroups are shown. Age, sex, race or ethnic group, the location of the infarct-related 
artery, the ejection fraction, and the time from the index myocardial infarction (MI) to randomization were prespecified. Race 
was self-reported. Diabetes and the highest Killip class during the index MI were not prespecified for the subgroup analysis. 
Originally, the cutoff point for age was 70 years, but early during the trial monitoring and before any analyses were performed, 
it was changed to 65 years because of insufficient numbers of patients older than 70. There was no significant interaction 
between treatment and subgroup variable as defined according to the prespecified value for interaction (P < 0.01). The use of 
a cutoff of 40% rather than the prespecified 50% for the ejection fraction did not alter the results. There was no interaction for 
the presence or absence of ST-segment elevation, Q-wave loss, or R-wave loss. LAD denotes left anterior descending artery. 
(Hochman et al.  NEJM Dec 7, 2006 p2405)
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hard to decipher from the figure. Note the 30% drop-outs
by five years, which is usefully made clear in Figure 16.
Bar charts are occasionally used to display summary
statistics such as means or percentages by treatment
groups. However, many authors correctly decide that such
relatively simple results are best shown in a table or text
rather than as a figure.
Figure 17 illustrates why a bar chart figure can sometimes
be of descriptive value, since the joint patterns of CD4
count and HIV RNA level during follow-up are "brought
to life" more readily than could be achieved in a table.
Figure 18 illustrates use of a bar chart for displaying
means of a quantitative outcome by treatment group,
before and after treatment. However, such means might
Exploratory disease-free survival subgroup analysis for 1 year of trastuzumab vs observationFigure 11
Exploratory disease-free survival subgroup analysis for 1 year of trastuzumab vs observation. (Smith et al.  Lancet Jan 6, 2007 
p33)
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be better plotted as points (as in Figures 13, 14, 15 and
16) rather than as bars[20]. Statistical uncertainty is use-
fully presented as error bars: the footnote states they are
standard deviations, but we suspect they intend standard
errors which would be more appropriate since it is the pre-
cision of each estimated mean rather than the individual
variation that matters here. Figure 18 does not inform us
as to the number of patients for each mean.
There are few instances where individual patient data are
displayed in a trial report. This is best confined to rela-
tively small trials, since such plots become too cluttered
with large numbers of patients. Figure 19 is one useful
plot of such individual data, which helps one to visualise
the individual falls in movement score in the neurostimu-
lation group. The accompanying box plot clarifies further,
with the median and interquartile ranges in the two
groups being clearly separated.
Figure 20 is another example of a box plot. The footnote
states "whiskers contain 100% of data, except for statisti-
cal outliers shown as individual points", though what
constitutes an outlier in undefined, and possibly
unnecessary. They are perhaps best called extreme values
since the term "outlier" incorrectly implies they are
invalid readings. With such skew distributions these plots
would have been clearer on a log scale.
Discussion
Figures are a key element of any trial report. They are often
more likely to be noticed by readers than text or tables,
and to be disseminated in conferences and discussions,
since by their very nature figures catch the eye more read-
ily, and hence have the potential to convey key results
more fully and immediately. Figures can reveal unex-
pected (and expected) patterns in data and graphs of
model estimates can encapsulate the entire picture of
what was learnt in a study, much more than can be done
in a table. To date, little attention has been paid to what
constitutes good practice for producing figures in trial
reports. Each journal has its own approach to use of
figures, but the key choice rests with what figures authors
include in their submitted articles.
Our survey of three months of trial reports in five key jour-
nals illustrates on the one hand that the great majority of
figures are of four main types (Flow diagram, Kaplan
Meier plot, Forest plot and Repeated measures over time),
but on the other hand there is a great diversity of style in
the way those Figures are presented.
The display of statistical uncertainty, i.e. standard errors
(SEs) or CIs, is an important component of many figures.
When comparing two groups it is useful for readers to
have insight into how the extent of overlap between SEs or
between CIs is related to the strength of evidence for a
difference between groups [21]. The following rough
guide works well when the two groups have SEs of similar
magnitude:
Breast cancer mortality results of the randomised mammog-raphy trials in w men ounger than 50 yearsFigure 12
Breast cancer mortality results of the randomised mammog-
raphy trials in women younger than 50 years. (Moss et al.  
Lancet Dec 9, 2006 p2059)
Mean Western Ontario and McMaster Universities osteoar-thritis index (W MAC) scores at rec uitment and at 3, 6, and 12 months' follow-upFigure 13
Mean Western Ontario and McMaster Universities osteoar-
thritis index (WOMAC) scores at recruitment and at 3, 6, 
and 12 months' follow-up. Top: WOMAC pain scores. Bot-
tom: WOMAC function scores. (Hay et al.  BMJ online Nov 11, 
2006 p5)
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Mean Scores Over Time for SF-36 Bodily Pain and Physical Function Scales and Oswestry Disability IndexFigure 14
Mean Scores Over Time for SF-36 Bodily Pain and Physical Function Scales and Oswestry Disability Index. Age- 
and sex-weighted population normative scores are plotted for Medical Outcomes Study 36-Item Short-Form Health Survey 
(SF-36) scales. To enhance readability, the plot symbols and error bars for the surgical group are slightly offset. Error bars indi-
cate 95% confidence intervals. (Weinstein et al.  JAMA Nov 22, 2006 p2447)
Change From Baseline to Week 72 in Mean and Maximum CIMT of the Common Carotid ArteryFigur 15
Change From Baseline to Week 72 in Mean and Maximum CIMT of the Common Carotid Artery. Values pre-
sented are least-square (LS) means using last observation carried forward. Error bars indicate SEs. A, Baseline LS mean, 0.771 
(SE, 0.008) mm for pioglitazone and 0.779 (SE, 0.008) mm for glimepiride. Treatment-group difference (pioglitazone – glimepir-
ide) at final visit, -0.013 (95% confidence interval, -0.024 to -0.002; P = .02). B, Baseline LS mean, 1.038 (SE, 0.0100) mm for 
pioglitazone and 1.042 (SE, 0.0100) mm for glimepiride. Treatment-group difference at final visit, -0.024 (95% confidence inter-
val, -0.042 to -0.006; P = .008). CIMT indicates carotid intima-media thickness. (Mazzone et al.  JAMA Dec 6, 2006 p2577)
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1) If there is any overlap between the standard error bars
then the difference is not statistically significant
2) If there is a gap between the standard error bars and
that gap itself exceeds one standard error then the differ-
ence is significant, at P < 0.035 in fact. Thus, a lesser gap
may fall short of conventional significance
3) If the 95% CIs do not overlap then we have strong evi-
dence of a difference, P < .006 in fact. So, a slight overlap
between two 95% CIs may still be statistically significant.
Of course, this guide should not substitute for the formal
presentation of P-values for comparisons of key interest.
A cynic might observe that i) authors lack imagination
and are over-conservative in their use of figures and ii)
authors are sloppy in the way they actually present figures.
The first point may be unduly harsh, since clinical trials
have a limited number of data types, and over time it has
become evident which types of figure work in practice.
Also, unconventional uses of figures, while having crea-
tive potential may carry the risk that some readers struggle
to understand and interpret them. Nevertheless some
types of figure may at present be underutilized, for
instance appropriate displays of individual patient data.
We feel there is more justification in the second criticism
above as regards sloppiness and inconsistencies in style.
Accordingly, we devote the rest of this Discussion to a list
of Recommendations for future practice.
Training Effects on Everyday Function by Self-reported Instrumental Activities of Daily Liv ng (IADL) DifficultySco esFigure 16
Training Effects on Everyday Function by Self-
reported Instrumental Activities of Daily Living 
(IADL) Difficulty Scores. The mean scores are Blom-
transformed. Error bars indicate SE. The sample sizes for 
each time point represent the number of cases with com-
plete data for the IADL difficulty score. (Willis et al.  JAMA Dec 
20, 2006 p2811)
Percentage of Follow-up Time during Which Participants Had a Specified CD4+ Count and HIV RNA LevelFigure 17
Percentage of Follow-up Time during Which Participants Had a Specified CD4+ Count and HIV RNA Level. 
For 28.8% of the 3666 person-years of follow-up in the drug conservation group (Panel A), the HIV RNA level was 400 copies 
per milliliter or less. Patients received antiretroviral therapy during 33% of the follow-up time. For 72.3% of the 3701 person-
years of follow-up in the viral suppression group (Panel B), the HIV RNA level was 400 copies per milliliter or less. Patients 
received antiretroviral therapy during 94% of the follow-up time. (SMART Study Group.  NEJM Nov 30, 2006 p2288)
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Hepatic Fat Content Assessed by Means of Magnetic Resonance Spectroscopy before and after the Study Treatment (Panel C); and Plasma Adiponectin Concentratio before and after the Study T eatment (Pan l D)Figure 18
Hepatic Fat Content Assessed by Means of Magnetic Resonance Spectroscopy before and after the Study 
Treatment (Panel C); and Plasma Adiponectin Concentrations before and after the Study Treatment (Panel 
D). In Panels C and D, P < 0.001 for the comparisons of the pioglitazone and placebo groups with the healthy controls both at 
baseline and at 6 months, except that the comparison of post-treatment plasma adiponectin concentrations in the pioglitazone 
group and the healthy controls was not significant. I bars and T bars denote standard deviations.(Belfort et al.  NEJM Nov 30, 
2006 p2302)
Changes in Movement Scores from Baseline to 3 Months and the Effects of 6 Months of Neurostimulation, as Compared with Sham StimulationFigur  19
Changes in Movement Scores from Baseline to 3 Months and the Effects of 6 Months of Neurostimulation, as 
Compared with Sham Stimulation. As shown in Panel A, patients receiving effective high-frequency neurostimulation of the 
internal globus pallidus for 3 months had a significantly greater improvement in dystonic symptoms, as assessed by blinded ratings 
with the use of the Burke-Fahn-Marsden Dystonia Rating Scale, than did patients receiving sham stimulation. Each symbol denotes 
the change in scores from baseline to 3 months. The box plots represent the median and interquartile range. I bars show the 
range for each group. The changes in movement symptoms throughout the trial are shown for patients who were initially assigned 
either to the neurostimulation group (Panel B) or the sham-stimulation group (Panel C). (Kupsch et al.  NEJM Nov 9, 2006 p1983)
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Effects of Treatment on Serum and Prostatic Androgen LevelsFigure 20
Effects of Treatment on Serum and Prostatic Androgen Levels. Both testosterone and dihydrotestosterone levels 
increased in serum after 6 months of treatment with testosterone replacement therapy (P < .001 by signed rank test). How-
ever, despite an increase in serum levels for testosterone to the mid-normal range, prostate tissue levels of the androgens did 
not change significantly. Boxes contain 50% of data with the inside horizontal line representing the median value; whiskers con-
tain 100% of data, except for statistical outliers shown as individual data points. (Marks et al.  JAMA Nov 15, 2006 p2356)
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Recommendations
First some issues relating to figures in general:
1) One needs to decide which results merit a figure
rather than a table. Some figures (e.g. Kaplan Meier
plots) would be cumbersome as a Table while others
(e.g. a bar chart of percentages) may be better in tabular
form or in the text.
2) Every figure needs the following: a good legend, clear
labelling, clarity of presentation and to stand alone in its
comprehensibility rather than needing explanation in
the text.
3) Figures should clearly identify each treatment group,
and require care in use of colours and background shad-
ing since many readers use black-and-white copies.
4) Figures should indicate the numbers of patients by
treatment group in each analysis presented.
5) Figures should display appropriate measures of uncer-
tainty, e.g. standard error bars or CIs.
6) Figures should often state the primary inferences to be
derived from them, e.g. estimates of treatment effect, their
CIs and P-values, since visual inspection alone could lead
to misleading interpretations by the reader.
7) The creation of high-quality figures requires careful
attention to overall principles of graph construction and
visual display as developed by specialists in this field
[1,2,4,6,7].
The following recommendations relate to the four main
types of Figure:
A) Flow Diagram
8) Every trial report should include a flow diagram, in line
with CONSORT guidelines [11,12].
9) The flow diagram should include the numbered flow of
participants throughout the trial, including the numbers
screened and eligible prior to randomization.
10) It is particularly important to provide the numbers in
each group lost to follow-up or excluded from analysis for
other reasons.
11) Some flow diagrams can become indigestible with too
many repeat words, especially with several treatment
arms. These may be better displayed as a Table without
loss of information.
B) Kaplan Meier plot
12) Plots should include numbers at risk over time under
the time axis.
13) The plot should not extend too far in time, to avoid
the numbers at risk becoming unduly small.
14) Plots with relatively low event rates should be dis-
played going up (i.e. cumulative percent with event on the
vertical axis) so that the detail is discernable.
15) Plots should often include standard error bars at
appropriate time points to convey statistical uncertainty.
To date this is rarely done.
C) Forest plot
16) In addition to estimates and 95% CIs for various sub-
groups, Forest plots should also include the overall esti-
mate and its CI. Drawing a vertical dotted line at the
overall estimate helps readers to spot any consistency (or
otherwise) across subgroups.
17) One can usefully use varying sizes of square at each
estimate to indicate which subgroups are based on a lot
(or a little) data.
18) For plots of hazard ratio, odds ratio or relative risk
a log scale is often preferable, leading to symmetric
CIs.
19) The risk scale should provide an appropriate degree of
detail, and make clear which direction indicates which
treatment is better.
20) Forest plots can usefully tabulate for each subgroup
some of the following: the numbers of patients and num-
bers with events by treatment, the estimate and its CI and
the interaction test P-value. However, this should not
result in excessively detailed information for what is an
exploratory subgroup analysis.
21) Interaction tests should be reported rather than sub-
group P-values. That is, the difference between "signifi-
cant" and "non-significant" subgroups may not be
statistically significant[22].
D) Repeated measures plot
22) The points for each estimate (usually means) at each
time point should be clearly marked and joined by lines
for each treatment in a clearly identified manner. With
several treatment groups it may be clearer to identify
groups by symbols rather than by lines.
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23) Measures of uncertainty, usually standard errors bars,
should be attached to each point, and the number of
patients included should be under the time axis.
24) It is useful to slightly stagger the groups so means and
standard errors don't overlap confusingly.
25) It is often better to plot mean changes from baseline,
rather than means, using analysis of covariance to present
baseline adjusted mean changes.
26) The method of analysis used to make inferences from
the repeated measures should be briefly stated on the plot,
and it may be useful to add some overall estimate of treat-
ment effect with CI and P-value.
Conclusion
In conclusion, we hope these useful pointers enhance the
quality of clinical trial reports with respect to use of fig-
ures. A similar enquiry to this may be of value for other
type of study eg reports of observational studies in
epidemiology, so that all journal articles pay appropriate
attention to the informative use of figures.
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